Sandoz has completed the acquisition of Just-Evotec Biologics EU SAS, enhancing its biosimilars manufacturing capabilities and positioning itself to capture significant market opportunities.
Overview of the Target
Sandoz has successfully completed the acquisition of Just-Evotec Biologics EU SAS (JEB SAS) from Evotec SE. This strategic acquisition encompasses the development and manufacturing facility located in Toulouse, France, along with an indefinite license for advanced continuous-manufacturing technology tailored for biosimilars. This move is a significant step that reinforces Sandoz's commitment to its biosimilars strategy, augments its internal drug substance development and manufacturing capabilities, and enhances operational efficiencies.
The acquisition of JEB SAS not only solidifies Sandoz's position within the industry but also prepares the company to leverage an estimated >USD 300 billion market opportunity stemming from the loss of exclusivity (LoE) of several key biologics in the coming decade. Richard Saynor, CEO of Sandoz, emphasized the necessity of biosimilars as a crucial component of healthcare and expressed the company’s ambition to be the premier leader in this rapidly evolving market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
France boasts a robust pharmaceutical sector, characterized by significant public and private investment in research and development. The country's strategic focus on biopharmaceuticals and biosimilars has positioned it as a key player
Similar Deals
Sandoz
invested in
Just-Evotec Biologics EU SAS
in 2025
in a Other deal
Disclosed details
Revenue: $10,400M